These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8730458)

  • 1. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients.
    Lago M; Pérez-García R; García de Vinuesa MS; Anaya F; Valderrábano F
    Nephron; 1996; 72(4):723-4. PubMed ID: 8730458
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 3. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
    Lui SF; Wong KC; Li PK; Lai KN
    Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the use of subcutaneous epoetin beta once a week really equivalent to a more frequent administration of the same total dose?
    Andrulli S; D'Amico M; Locatelli F
    Nephrol Dial Transplant; 2001 Dec; 16(12):2439-40. PubMed ID: 11733645
    [No Abstract]   [Full Text] [Related]  

  • 8. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 9. [A multicenter trial of Recormon within the framework of international controlled research].
    Tareeva IE; Nikolaev AIu; Klepikov PV; Lashutin SV; Riabov SI; Shostka GD; Ermolenko VM; Rozental' RL; Vorob'ev PA; Miagkov AV
    Ter Arkh; 1992; 64(8):59-62. PubMed ID: 1440400
    [No Abstract]   [Full Text] [Related]  

  • 10. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin.
    Veys N; Vanholder R; Lameire N
    Am J Nephrol; 1992; 12(1-2):68-72. PubMed ID: 1415368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study.
    Granolleras C; Leskopf W; Shaldon S; Fourcade J
    Clin Nephrol; 1991 Dec; 36(6):294-8. PubMed ID: 1769141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration.
    Zehnder C; Blumberg A
    Nephron; 1991; 57(4):485-6. PubMed ID: 2046836
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of changing s.c. epoetin alfa administration from thrice weekly to once weekly in hemodialysis patients.
    To LL; Stoner CP
    Am J Health Syst Pharm; 2003 May; 60(9):931-4. PubMed ID: 12756944
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients.
    Bommer J; Barth HP; Zeier M; Mandelbaum A; Bommer G; Ritz E; Reichel H; Novack R
    Contrib Nephrol; 1991; 88():136-43. PubMed ID: 2040175
    [No Abstract]   [Full Text] [Related]  

  • 19. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
    Rozental' RL; Zezina LIu; Spudass AV
    Ter Arkh; 1991; 63(12):110-3. PubMed ID: 1803587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: a multicenter Italian experience.
    Buccianti G; Colombi L; Battistel V
    Haematologica; 1993; 78(2):111-7. PubMed ID: 8349186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.